BOSTON–(BUSINESS WIRE)–Foundation Medicine’s molecular residual disease (MRD) assay, FoundationOne®MRD, has been named a 2026 Top Innovation by The Scientist.
BOSTON–(BUSINESS WIRE)–Foundation Medicine’s molecular residual disease (MRD) assay, FoundationOne®MRD, has been named a 2026 Top Innovation by The Scientist.